Introduction
The RAS association domain family 1A (RASSF1A) is a tumor suppressor gene on chromosome 3p21 that is epigenetically inactivated in a variety of human cancers (Dammann et al., 2000 Agathanggelou et al., 2005) . The functional and mechanistic roles of RASS-F1A in suppressing tumorigenesis have been the subject of intense investigation in the last decade (for reviews see (Donninger et al., 2007; van der Weyden and Adams, 2007; Richter et al., 2009) ). RASSF1A is thought to regulate several functional pathways. These include, among others, control of cell-cycle progression by inhibition of cyclin D1 expression (Shivakumar et al., 2002) and modulation of apoptosis through the interaction with Ras, NORE1, MST kinases, CNK1 and MOAP-1 (Vos et al., 2003; Praskova et al., 2004; Rabizadeh et al., 2004; Baksh et al., 2005; Matallanas et al., 2007; Foley et al., 2008) . In addition, RASSF1A has been shown to control microtubule stability by interacting with the microtubule-associated proteins, microtubule-associated protein 1B and C19 open reading frame 5 protein, thus modulating spindle dynamics and, potentially, genomic stability Dallol et al., 2004; Vos et al., 2004; Song et al., 2005) . Consistent with this role, RASSF1A colocalizes with the microtubule network during interphase, and is found at the centrosomes and spindle poles from interphase to telophase and at the midbody during cytokinesis Song et al., 2005; Guo et al., 2007) . We have recently determined that RASSF1A is a component of the mammalian counterpart of the Drosophila Hippo/Salvador/Lats tumor-suppressor pathway. In mammals, this complex is thought to be involved in controlling mitotic exit (Guo et al., 2007) . The importance of the mammalian Hippo pathway in tumor suppression has recently been demonstrated in mouse models where key components of the pathway were either knocked out or overexpressed (Zender et al., 2006; Zhou et al., 2009) . Of significance, stable or transient ablation of RASSF1A leads to several mitotic abnormalities, including centrosome amplification, cytokinesis failure and tetraploidization, which are known to increase the risk of genomic instability (Song et al., 2004; Guo et al., 2007) . Surprisingly, Rassf1a-knockout mice did not show any evidence of significant aneuploidy (that is, gain and loss of whole chromosomes or chromosomal domains), although these animals were more susceptible to spontaneous and carcinogen-induced tumorigenesis than wild-type littermates van der Weyden et al., 2005) . These observations strongly suggest that RASSF1A function alone is not a key determinant in maintaining genomic integrity and additional inactivation of other functional pathways is most likely required to drive cells towards aneuploidy during tumorigenesis in vivo.
Mitotic dysfunction is often associated with tetraploidization (Caldwell et al., 2007; Ganem et al., 2007) . Tetraploid cells are genetically unstable and highly predisposed to the development of aneuploidy during neoplastic progression (Storchova and Kuffer, 2008) . Under normal conditions, a postmitotic 'tetraploidy checkpoint' prevents endoreduplication of DNA after a failed cytokinesis and blocks progression to S-phase, thus allowing repair of damaged DNA and/or removal of aberrant polyploid cells through apoptosis. This postmitotic G1 checkpoint is under strict surveillance of the p53 tumor suppressor gene, the gatekeeper of DNA integrity and cell survival (Cross et al., 1995; Giono and Manfredi, 2006) . In fact, lack of p53 is often associated with development of tetraploidy in vitro and in vivo (Livingstone et al., 1992; Cross et al., 1995) , and a direct epidemiological link has been established between p53 loss and tetraploidy in certain preneoplastic conditions, such as Barrett's esophagus (Galipeau et al., 1996) . More recently, Fujiwara et al. (2005) have shown that tetraploid p53 À/À mouse cells, but not isogenic diploid cells, can initiate tumor formation when transplanted into immunodeficient mice. This is so far the most compelling evidence that unrestrained proliferation of tetraploid cells can trigger tumorigenesis. Accumulation of tetraploid cells can occur spontaneously in cultured primary p53 À/À mouse mammary epithelial cells and can escalate following treatment with microtubule and cytokinesis inhibitors (Senovilla et al., 2009) . The functional link between the p53-dependent tetraploidy checkpoint and the mitotic spindle checkpoint is now well established (Vogel et al., 2004; Burds et al., 2005; Chi et al., 2008) .
Here, we investigated whether a functional p53 in Rassf1a-deficient cells, exhibiting cytokinesis failure, could prevent progression to aneuploidy by blocking endoreduplication of the resulting tetraploid cells. If this holds true, we would expect that loss of p53 on a Rassf1a-null background would enhance mitotic dysfunction, tetraploidization and tumorigenicity due to inability to properly monitor mitotic progression and maintain genomic integrity. To study the contribution of p53 to the Rassf1a-knockout phenotype and vice versa, we have generated single-and compound-mutant mice lacking either one or both the p53 or Rassf1a alleles. Our results are indicative of increased tumor predisposition and genomic instability in mice lacking both the Rassf1a and p53 tumor suppressor genes, whereas a more moderate, yet tumor-prone phenotype was observed in Rassf1a À/À p53 þ /À animals. Furthermore, considering that promoter methylation of RASSF1A and mutation of p53 are the most frequent epigenetic and genetic events, respectively, in human cancers, we have generated a valuable experimental model to study the relative impact of Rassf1a and p53 in tumor development.
Results
Effects of p53 gene removal on tumor formation in Rassf1a knockout mice To assess the contribution of p53 loss of function to the Rassf1a-knockout phenotype and vice versa, we have generated single-and double-mutant mice that lack the p53 and Rassf1a gene products. Rassf1a À/À 129S1 mice were bred with p53 À/À C57BL/6 N12 mice (Donehower et al., 1992) . Intercrosses of these two strains have produced cohorts of single-and compound-mutant mice, on a hybrid C57BL/6 Â 129 genetic background (Figure 1a ). At first, we observed no The following cohorts were placed on tumor watch throughout a period of up to 20-month:
Sick and tumor-bearing mice were promptly euthanized and their age at the time of morbidity/death was recorded before assembling the Kaplan-Meier curve. The number of mice (n) used to establish the survival curve is indicated for each group.
Synergic role of Rassf1a and p53 in cancer S Tommasi et al abnormalities and/or developmental defects in any of the mutant cohorts. Mice were viable and fertile, and borne at the expected Mendelian frequencies (Supplementary Table S1 ). The following seven subgroups were then monitored for spontaneous tumor development or signs of morbidity throughout a 20-month time period:
. Consistent with landmark studies (Donehower et al., 1992; Jacks et al., 1994; Purdie et al., 1994) , p53-knockout mice developed tumors within the first several months of life and all succumbed to malignancies by 10 months of age with a median tumor-free survival time of 158 days (Figure 1b) . Heterozygous deletion of Rassf1a did not affect the already pronounced phenotype and tumorigenicity of p53 À/À mice (Rassf1a þ /À p53 À/À mice, median time of 163 days; P ¼ 0.886). Removal of both Rassf1a alleles had, however, a substantial impact on tumor predisposition and survival rate of p53-null animals, as double-knockout mice developed tumors significantly faster than p53 À/À mice (with a median time of 136 days versus 158 days in p53 À/À mice, P ¼ 0.0207; Figure 1b ). Of significance, all animals in the Rassf1a
À/À subgroup succumbed to cancer within 8 months of age (Figure 1b) .
To evaluate the contribution from the loss of a single p53 allele to the Rassf1a phenotype, we have also monitored animals that inherited a normal p53 allele. A total of 16 out of 44 (36%) Rassf1a À/À p53 þ /À mice versus 6 of 29 (21%) p53 þ /À mice developed tumors by 20 months of age. The Kaplan-Meier plots of these two cohorts were clearly not superimposable; however, the difference in the rates of tumor incidence was not significant, according to the Log-rank statistical test (P ¼ 0.22). When compared with Rassf1a single-knockout counterparts, Rassf1a
þ /À mice were more inclined to develop tumors, and showed a drastic reduction in the overall survival rate (P ¼ 0.0029).
Tumor spectrum and tumor burden in single-and double-mutant mice We characterized tumor load and type, as well as tissue distribution in the six aberrant genotypes. Table 1 summarizes the tumor burden and spectrum observed in Rassf1a
Rassf1a
À/À p53 À/À mice. As predicted from the KaplanMeier plot, Rassf1a À/À p53 À/À mice were significantly more tumor prone (96% animals with neoplasia) than Rassf1a À/À p53 þ / þ mice (9% animals with neoplasia), indicating that loss of p53 strongly accentuates the Rassf1a-null mice predisposition to neoplastic disease (Po0.0001). The tumor incidence in Rassf1a À/À p53 À/À mice (96%) was, however, comparable with that of Rassf1a þ /À p53 À/À (96%) and p53 À/À mice (89%), with a mean of 1.8 ± 1.1 ( ± s.d.) tumors/mouse in the three p53-null genotypes ( Figure 2A ). Yet, double-mutant animals died of malignancies much faster than Rassf1a þ /À p53 À/À and p53 À/À littermates ( Figure 1b ).
Loss of p53 appears to dictate the tumor spectrum, as we observed the same tumor types (mostly lymphoma and sarcoma), and target organs in double-mutant mice as well as in Rassf1a þ /À p53 À/À and p53 À/À animals ( Table 1 ). The vast majority of lymphomas (89-91% of all lymphoma-bearing mice from the three p53-null cohorts) emerged in the thymus, and on microscopic examination showed a large number of mitoses, many apoptotic cells, and numerous mitotic figures. Other hematopoietic tissues, such as spleen and liver, were also targeted by high-grade lymphoma, and most of the mice with thymic lymphoma displayed marked spleenomegaly and/or hepatomegaly, with a four-to fivefold increase in size compared with same-age control littermates. Similarly to the p53
À/À p53 À/À mice suffered also from undifferentiated high-grade sarcomas, such as chondrosarcomas and angiosarcomas (absent in Rassf1a À/À animals), confirming that Rassf1a depletion did not interfere with the tumor spectrum and burden already imposed by 
k FD: number of mice found dead and excluded from the analysis, as we were unable to determine the causes of death based on the necropsy report.
Synergic role of Rassf1a and p53 in cancer S Tommasi et al p53 loss. Representative hematoxylin and eosin sections of Rassf1a Figure 2B : panels a-f.
One may argue that differences in phenotype might go undetected because of the short life span of the three p53-null cohorts. To rule out this possibility, we have 
1.77 ± 1.04 1.77 ± 1.27 1.80 ± 1.22 1.88 ± 0.89 1.33 ± 0.82 1.50 ± 1 Figure 2 Tumor suceptibility in single-and double-compound mice. (A) Tumor multiplicity in Rassf1a single-knockout mice were either tumor free or developed only one type of tumor per animal ( Figure 2A and Table 1 ). Histological sections of Rassf1a
tumors are displayed in Figure 2B : panels g-i. A total of 9 out of 44 Rassf1a À/À p53 þ /À mice developed multiple tumors (21%) with a mean of 1.9±0.9 tumors/animal, as compared with 3% of p53 þ /À mice (1/29, Po0.05) with a mean of 1.33 ± 0.8 tumors/animal (Figure 2A) . The trends showed a tumor burden of 68% in Rassf1a
þ /À mice (30 tumors in total) as compared with 28% in p53 þ /À mice (8 tumors in total, Po0.001) and 14% in Rassf1a À/À mice (6 tumors in total, Po0.0001). Furthermore, Rassf1a
À/À p53 þ /À mice displayed higher incidence of lymphoma compared with single-mutant animals (p53 þ /À mice, Po0.03 and Rassf1a À/À mice, Po0.001), though the number of mice with thymic lymphoma was greatly reduced (less than 50%). The apparent increase of oncogenic events observed in Rassf1a À/À p53 þ /À mice translated into a significantly shorter tumor latency and life span compared with Rassf1a À/À mice but not compared with p53 þ /À mice. This further highlights the overriding role of p53 in tumor suppression (Figure 1b) .
Misregulated cell cycle and increased polyploidy in double-knockout cells
To determine the impact of loss of Rassf1a and p53 on cell proliferation, we compared the DNA content and cell-cycle profile of asynchronously growing mouse embryonic fibroblasts (MEFs) of different genotypes. Cells derived from Rassf1a À/À p53 þ /À and Rassf1a À/À embryos displayed a similar flow cytometric profile to that of wild-type MEFs (Figure 3 , panels a, c and e). Conversely, early passage mouse fibroblasts derived from Rassf1a À/À p53 À/À embryos exhibited the most prominent G2/M and polyploid fractions compared with other knockout fibroblasts cultured under identical conditions (31% cells with a 4-N DNA content, mostly a diploid G2/M, and 23% cells with a content 44N; Figure 3 : panel k). The rate of tetraploid cells was enhanced on removal of both p53 alleles, along with a decrease in Rassf1a dosage (from approximately 14% in Figure 3 : panels g, i and k). We have also treated MEFs of different genotypes with the chemotherapeutic agent doxorubicin, which causes several forms of DNA damage, including doublestrand breaks. Doxorubicin triggers a p53-dependent G1 arrest through activation of the ataxia telangiectasiamutated protein kinase as well as a G2/M arrest, independent of the p53 gene (Attardi et al., 2004; Lobrich and Jeggo, 2007) . In line with previous data, p53 À/À MEFs exposed to doxorubicin failed to arrest in G1 (due to checkpoint failure), and accumulated at the G2/M phase (33%), followed by emergence of polyploid cells (28%; Figure 3 : panel h). Loss of Rassf1a did not seem to interfere with the checkpoint execution as long as one allele of p53 remained active to carry out the normal function (Figure 3 : panels d and f). However, cells lacking both Rassf1a alleles on a p53 À/À background seemed to undergo extensive mitotic slippage and endoreduplication after DNA damage, resulting in a substantial increase in the octaploid population (from 26 and 28% in Rassf1a
cells, respectively, to 40% in Rassf1a À/À p53 À/À fibroblasts; Figure 3 : panels h, j and l).
Cytokinesis defects and aneuploidy are accentuated in Rassf1a
À/À p53 À/À cells It is widely recognized that cytokinesis failure can lead to the formation of genetically unstable tetraploid cells with high oncogenic potential (Fujiwara et al., 2005; Shi and King, 2005) . To test whether the increased polyploidy observed in the Rassf1a À/À p53 À/À phenotype was the result of enhanced mitotic defects, we monitored MEFs derived from wild-type, Rassf1a
littermates by time-lapse video microscopy. The length of mitosis was determined visually from the time preceding the rounding up of the parent cell (prophase) to the complete separation into two daughter cells. As previously shown (Lanni and Jacks, 1998) , early passage p53 knockout cells (Rassf1a
) progressed normally through mitosis and completed cytokinesis in a time frame comparable with that of normal control (less than 60 min; Figures 4a and b) . Conversely, Rassf1a þ /À p53 À/À and Rassf1a À/À p53 À/À fibroblasts required a longer time to traverse mitosis (approximately 20 min longer; Figures 4a and b) . In line with the Rassf1a À/À phenotype (Guo et al., 2007) , we observed a significant fraction of Rassf1a À/À p53 À/À cells that failed to complete cytokinesis, resulting in the emergence of binucleated cells (40 versus 14% of p53 À/À cells; P ¼ 0.021). Although p53-null cells are per se predisposed to aberrant cell divisions, Rassf1a appeared to have a crucial role in the development of tetraploid cells because we observed a high portion of failed mitosis in p53 À/À fibroblasts lacking one Rassf1a allele. To establish whether simultaneous loss of Rassf1a and p53 predisposed cells to increased aneuploidy, we examined the karyotypes of cultured fibroblasts derived from wild-type, Rassf1a
embryos. In total, 30 metaphase spreads per genotype were analyzed using standard cytogenetic G-banding protocols. Metaphases versus chromosome numbers are given in Figure 4c . The overall results confirmed that loss of both p53 alleles on a Rassf1a-null background strongly predisposes cells to aneuploidy (Figure 4c , lower panel) and other chromosomal abnormalities. Conversely, more than 60% of Rassf1a À/À p53 þ /À and control cells were either diploid or near diploid (versus B37% in Rassf1a À/À p53 À/À mice; Figure 4c , middle and upper panels).
Concomitant loss of Rassf1a and p53 strongly predisposes mice to aneuploid tumors Despite the similar tumor burden, Rassf1a À/À p53 À/À mice succumbed to malignancies significantly faster than 
We questioned whether enhanced tumor development and decreased survival rate was the result of increased karyotypic aberrations as suggested by the cytogenetic data on mouse fibroblasts. We performed interphase fluorescence in situ hybridization analysis on sections of Figure 3 Concomitant loss of Rassf1a and p53 tumor suppressor genes enhances tetraploidization. FACS analysis of mouse embryonic fibroblasts derived from single-and compound-mutant mice. Asynchronously growing fibroblasts were seeded at 0.7-1 Â 10 6 cells per 100-mm plate 1 day before the experiment. Subsequently, cells were left either untreated (a, c, e, g, i, k) or incubated with doxorubicin for 18 h (b, d, f, h, j, l) . Synergic role of Rassf1a and p53 in cancer S Tommasi et al thymic lymphomas derived from Rassf1a (Figure 5a) . A normal thymus from a Rassf1a À/À p53 þ / þ mouse was used as a control. A total of 200 cells were scored per genotype and the results were plotted in Figure 5b . On the basis of chromosome 8 signal, Rassf1a À/À p53 À/À tumors displayed the highest percentage of aneuploid cells, compared with Rassf1a
Rassf1a
þ /À p53 À/À specimens (Po0.006). The tumor karyotyping results are clearly in agreement with the in vitro cytogenetic data and can account for the highgrade tumor invasiveness and poor survival rate observed in Rassf1a À/À p53 À/À mice.
Discussion
Tetraploid cells can arise from viral-induced cell fusion, mitotic slippage or cytokinesis failure and evolve into tumorigenic aneuploid cells with multiple structural and numerical chromosomal aberrations (Storchova and Pellman, 2004; Holland and Cleveland, 2009 ). Aneuploidy and chromosomal instability are two hallmarks of human cancers and are frequently associated with high-grade invasiveness and poor prognosis (Giaretti, 1994; Segers et al., 1994; Verdoodt et al., 1994) . In human tumors, aneuploidy often coincides with inactivation of p53. However, there is increasing evidence that loss of p53 alone is not the sole cause of 
Rassf1a
-/-p53 -/-(n = 15) 
À/À and Rassf1a À/À p53 À/À fibroblasts are shown. White arrows and arrowheads indicate the dividing parent and daughter cells, respectively. The time frame required to complete cytokinesis is also displayed. (b) The diagram summarizes the outcome of mitoses in Rassf1a aneuploidy, but rather cooperates with other oncogenic events, such as activation of oncogenes or loss of additional tumor suppressor genes, to promote genomic instability (Duensing and Duensing, 2005) . Here, we investigated whether simultaneous loss of Rassf1a (leading to mitotic dysfunction) and of p53 (resulting in tetraploidy checkpoint failure) will produce increased levels of aneuploidy, genomic instability and tumorigenesis. To test this hypothesis, we have intercrossed Rassf1a-knockout mice with mice lacking the p53 gene and obtained a combination of single-and compound-mutant cohorts. Rassf1a À/À p53 À/À doubleknockout mice were viable and fertile, and developed normally. However, these mice were remarkably tumor prone and succumbed to malignancies significantly faster than single-knockout littermates, with a tumorfree median survival time of 136 days (versus 158 days in p53 À/À mice, P ¼ 0.0207 and 4600 days in Rassf1a À/À mice, Po0.0001; Figure 1b) . Conversely, Rassf1a-null mice retaining one functional p53 allele displayed a Figure 5 Tumor karyotyping by fluorescence in situ hybridization (FISH). To determine ploidy level of mouse PET sections, interphase FISH analysis was performed using a labeled mouse BAC probe for chromosome 8, as described in Materials and methods. moderate, yet tumor-prone phenotype, with increased tumor multiplicity compared with single knockouts ( Figure 2A and Table 1 ). Rassf1a À/À p53 À/À animals developed mainly highgrade lymphomas (81% of the mice and mostly thymic lymphomas), followed by undifferentiated sarcomas (33%; Table 1 and Figure 2B ). These are the two most frequent tumor types detected in p53-null littermates, but not in Rassf1a À/À animals, which usually develop B-cell lymphoma and lung adenoma van der Weyden et al., 2005) . We observed no substantial differences, in terms of tumor load or tumor multiplicity, among Rassf1a
and p53 À/À mice (Table 1 and Figure 2A ), indicating that p53 is phenotypically dominant over Rassf1a and dictates the tumor spectrum and burden in doubleknockout animals. Yet, lack of Rassf1a on a p53 À/À background could significantly shorten tumor latency, consistent with a synergistic role of Rassf1a in promoting transformation.
Several lines of evidence suggest the potential function of RASSF1A in controlling microtubule dynamics and mitotic progression (van der Weyden et al., 2005; Guo et al., 2007) . Of significance, loss of Rassf1a leads to mitotic defects and cytokinesis failure, as well as tetraploidization in MEFs (Guo et al., 2007) . Transient knockdown of RASSF1A in human foreskin fibroblasts also causes mitotic abnormalities, such as multiple centrosomes and lagging chromosomes, which are known to increase the risk of chromosomal imbalances (Song et al., 2004) . Nevertheless, no gross genomic instability has been observed in Rassf1a-knockout mice, although these mice are known to be susceptible to spontaneous carcinogenesis van der Weyden et al., 2005) . Presumably, an intact p53-dependent postmitotic checkpoint, even in the absence of RASSF1A, is sufficient to limit the proliferative capacity of tetraploid cells and progression to genomic decay. On the other hand, the mitotic defects generated in cells lacking Rassf1a are likely to be unmasked by loss of p53 activity, thus resulting in unrestrained growth of polyploid cells and progression to aneuploidy. On cellcycle profiling, we observed the largest increment in the number of cells with DNA content 44N (23%) in fibroblasts lacking both p53 and Rassf1a activities. These cells are likely to have arisen from increased cytokinesis flaws (Figure 4b ). Higher levels of tetraploid cells accumulated following DNA damage induced by doxorubicin, which normally activates the p53-dependent G1 arrest (40% polyploidy in Rassf1a À/À p53 À/À fibroblasts as compared with 26 and 28% polyploidy in Rassf1a þ /À p53 À/À and Rassf1a þ / þ p53 À/À cells, respectively). These data strongly suggest that concomitant loss of Rassf1a and p53 promotes mitotic aberrations and predisposes cells to accelerated genomic instability. In our experiments, expression of a single copy of p53 was sufficient to resume normal checkpoint execution and override the drug-induced polyploidy, even in the absence of Rassf1a (Figure 3, panel f) .
The increased levels of polyploidy observed in the Rassf1a À/À p53 À/À genotype were not deleterious per se, as these mice did not die in utero or showed developmental defects. However, aberrant endoreduplication, associated with mitotic defects, could easily lead to karyotypic abnormalities and high chromosomal instability. We have performed cytogenetic analyses on MEFs derived from wild-type and compound mutant embryos. Consistent with fluorescence-activated cell sorting analysis, metaphase spreads of wild-type and Rassf1a À/À p53 þ /À fibroblasts exhibited a mostly diploid population with minor chromosomal aberrations (Figure 4c, upper and middle panels) . On the other hand, cytogenetic examination of MEFs derived from Rassf1a À/À p53 À/À embryos showed a prevalent polyploid karyotype (63.3%), with nonclonal aberrations and numerous gains and losses of chromosomes (Figure 4c , lower panel). In particular, we observed recurrent losses of chromosomes 1, 4, 7 and 13 in Rassf1a À/À p53 À/À cells, but not in other genotypes. Gains and losses of specific chromosomal domains, which are per se functionally important and/or may act synergistically with Rassf1a and p53 in suppressing tumorigenesis, can provide a selective growth advantage and profoundly influence tumor progression.
To further assess whether the in vitro cytogenetic data recapitulate the tumor karyotype, we have also analyzed thymic lymphomas derived from single-and compoundmutant mice by interphase fluorescence in situ hybridization. We observed a considerable fraction of aneuploid cells in Rassf1a þ /À p53 À/À and p53 À/À tumors as compared with normal thymus (13-14% gain/loss of chromosome 8, Figure 5b ). This is consistent with previous reports showing that thymic lymphoma as well as cells isolated from nonmalignant tissues in mice deficient in p53 are often aneuploid (Donehower et al., 1992; Jacks et al., 1994; Fukasawa et al., 1997) . However, a significantly higher percentage of tumor cells from double-knockout animals contained three or more chromosome 8 copies (Po0.006 compared with the other genotypes, Figure 5b ). These findings indicate that Rassf1a À/À p53 À/À mice accumulate deleterious rates of chromosomal aberrations, which strongly predispose these animals to aggressive tumor development and poor survival (Supplementary Figure 1) . Conversely, a slower tumor growth due to lower levels of aneuploidy and chromosome rearrangements, could account for the more attenuated tumor phenotype observed in Rassf1a À/À p53 þ /À mice, although these mice often developed multiple tumors (Supplementary Figure 1) .
In epithelial cancers, silencing of RASSF1A by promoter methylation occurs early during tumorigenesis and precedes inactivation of the p53 gene. However, the mechanisms by which loss of RASSF1A may contribute to tumor initiation remain elusive. In this study, we have provided the first experimental evidence for a synergistic role of Rassf1a and p53 in promoting genomic instability and tumorigenicity. Our data support a model whereby mitotic dysfunction and tetraploidy generated in absence of Rassf1a promote genomic instability and cancer onset, whereas the rate of tumor progression as well as the tumor spectrum and burden are governed by the status of the p53 alleles.
